aBLA Filing Intelligence & Biosimilar Opportunity

Winrevair

Sotatercept-Csrk

Antihypertensive

Subcutaneous Injection

Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.

Approval Date

26-Mar-24

Data Exclusivity Expiry

26-Mar-28

Market Exclusivity Expiry

26-Mar-36

Commercial snapshot

Market performance & projections

Revenue ($M)

1,443

CAGR (%)

41.60%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2,768

2027

3,859

2028

4,851

2029

5,802

2030

6,623

2031

7,421

2032

8,196

Molecule profile

Details & specifications

Molecule

Sotatercept-Csrk

Innovator

MERCK & CO., INC. (MSD)

Dosage Form

Subcutaneous Injection

Strength

45 mg lyophilized cake or powder, 60 mg lyophilized cake or powder

Therapeutic Category

Antihypertensive

Usage

To treat pulmonary arterial hypertension

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets